YolTech Raises 300 Million Yuan Series B, Pushing In‑Vivo Gene‑Editing to the Forefront
The AstraZeneca‑CICC Medical Industry Fund announced that it led a Series B financing round for China‑based...
YolTech Therapeutics
YolTech’s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment
China-based YolTech Therapeutics announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products...
YolTech Therapeutics Receives NMPA Clearance for YOLT-101 in HeFH Clinical Study
Shanghai-based YolTech Therapeutics announced that it has received clearance from the National Medical Products Administration...
YolTech Receives FDA Clearance for PCSK9-Targeted Base Editing Drug YOLT-101
Shanghai-based YolTech Therapeutics announced that it has received clearance from the US Food and Drug...
Salubris Pharma’s YOLT-101 Gene Editing Drug Accepted for NMPA Review
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced that the National Medical Products Administration...
YolTech Therapeutics’ YOLT-203 Shows Promise in Primary Hyperoxaluria Type 1 Trial
YolTech Therapeutics, a Shanghai-based startup specializing in lipid nanoparticle delivery and gene editing, announced positive...
YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia
Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has...
YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial
Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo...
Shenzhen Salubris Pharmaceuticals Inks Licensing Deal for YolTech Therapeutics’ YOLT-101 Gene Editing Therapy
Shenzhen Salubris Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company listed on the Shenzhen Stock Exchange...
uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy
China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell...
Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics
China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has...